HRP20191511T1 - Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba - Google Patents
Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba Download PDFInfo
- Publication number
- HRP20191511T1 HRP20191511T1 HRP20191511T HRP20191511T1 HR P20191511 T1 HRP20191511 T1 HR P20191511T1 HR P20191511 T HRP20191511 T HR P20191511T HR P20191511 T1 HRP20191511 T1 HR P20191511T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- fusion protein
- cdkl5
- seq
- use according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946280P | 2014-02-28 | 2014-02-28 | |
| PCT/IB2015/000999 WO2015128746A2 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
| EP15736034.8A EP3110837B1 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191511T1 true HRP20191511T1 (hr) | 2019-11-29 |
Family
ID=53539745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191511 HRP20191511T1 (hr) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba |
| HRP20211324TT HRP20211324T1 (hr) | 2014-02-28 | 2021-08-17 | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije, i njihova uporaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211324TT HRP20211324T1 (hr) | 2014-02-28 | 2021-08-17 | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije, i njihova uporaba |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3110837T1 (sl) * | 2014-02-28 | 2019-12-31 | Alma Mater Studiorum - Universita Di Bologna | Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba |
| BR112018077225A2 (pt) * | 2016-06-28 | 2019-04-09 | Alma Mater Studiorum - Università di Bologna | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas |
| KR20200090889A (ko) * | 2017-11-30 | 2020-07-29 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Cdkl5 발현 변이체 및 cdkl5 융합 단백질 |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| CA3156506A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| IT202000025423A1 (it) * | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| MX2023006445A (es) | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Composiciones y usos de estas para el tratamiento del síndrome de angelman. |
| JP2024531296A (ja) * | 2021-08-18 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 組換えａａｖ製剤 |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2815582A1 (en) * | 2010-10-25 | 2012-05-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Treatment of mecp2-associated disorders |
| SI3110837T1 (sl) * | 2014-02-28 | 2019-12-31 | Alma Mater Studiorum - Universita Di Bologna | Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba |
-
2015
- 2015-02-27 SI SI201530884T patent/SI3110837T1/sl unknown
- 2015-02-27 EA EA202190727A patent/EA202190727A3/ru unknown
- 2015-02-27 MX MX2020001223A patent/MX392778B/es unknown
- 2015-02-27 LT LTEP19179287.8T patent/LT3608334T/lt unknown
- 2015-02-27 HR HRP20191511 patent/HRP20191511T1/hr unknown
- 2015-02-27 SI SI201531680T patent/SI3608334T1/sl unknown
- 2015-02-27 SM SM20210478T patent/SMT202100478T1/it unknown
- 2015-02-27 LT LTEP15736034.8T patent/LT3110837T/lt unknown
- 2015-02-27 SG SG10202000537RA patent/SG10202000537RA/en unknown
- 2015-02-27 SM SM20190504T patent/SMT201900504T1/it unknown
- 2015-02-27 AU AU2015221860A patent/AU2015221860B2/en active Active
- 2015-02-27 WO PCT/IB2015/000999 patent/WO2015128746A2/en not_active Ceased
- 2015-02-27 DK DK19179287.8T patent/DK3608334T3/da active
- 2015-02-27 HU HUE19179287A patent/HUE055282T2/hu unknown
- 2015-02-27 CR CR20160392A patent/CR20160392A/es unknown
- 2015-02-27 SG SG11201606863YA patent/SG11201606863YA/en unknown
- 2015-02-27 PE PE2016001528A patent/PE20161406A1/es not_active Application Discontinuation
- 2015-02-27 CA CA2940401A patent/CA2940401C/en active Active
- 2015-02-27 PL PL19179287T patent/PL3608334T3/pl unknown
- 2015-02-27 PT PT191792878T patent/PT3608334T/pt unknown
- 2015-02-27 DK DK15736034.8T patent/DK3110837T3/da active
- 2015-02-27 MX MX2016011167A patent/MX2016011167A/es active IP Right Grant
- 2015-02-27 ES ES15736034T patent/ES2745335T3/es active Active
- 2015-02-27 EP EP15736034.8A patent/EP3110837B1/en active Active
- 2015-02-27 PL PL15736034T patent/PL3110837T3/pl unknown
- 2015-02-27 EP EP19179287.8A patent/EP3608334B1/en active Active
- 2015-02-27 KR KR1020167026521A patent/KR102307276B1/ko active Active
- 2015-02-27 BR BR112016019868-9A patent/BR112016019868B1/pt not_active IP Right Cessation
- 2015-02-27 RS RS20211041A patent/RS62244B1/sr unknown
- 2015-02-27 MY MYPI2016001567A patent/MY181566A/en unknown
- 2015-02-27 HU HUE15736034A patent/HUE045393T2/hu unknown
- 2015-02-27 RS RSP20191144 patent/RS59344B1/sr unknown
- 2015-02-27 EA EA201691691A patent/EA038000B1/ru unknown
- 2015-02-27 ES ES19179287T patent/ES2885245T3/es active Active
- 2015-02-27 JP JP2016553630A patent/JP6629747B2/ja active Active
- 2015-02-27 US US14/633,757 patent/US9290746B2/en active Active
- 2015-02-27 CN CN201580010858.9A patent/CN106255706A/zh active Pending
- 2015-02-27 PT PT15736034T patent/PT3110837T/pt unknown
-
2016
- 2016-03-21 US US15/075,457 patent/US9944910B2/en active Active
- 2016-08-23 DO DO2016000220A patent/DOP2016000220A/es unknown
- 2016-08-24 CL CL2016002142A patent/CL2016002142A1/es unknown
- 2016-08-25 IL IL247481A patent/IL247481B/en active IP Right Grant
- 2016-08-25 PH PH12016501689A patent/PH12016501689B1/en unknown
- 2016-08-26 NI NI201600127A patent/NI201600127A/es unknown
- 2016-08-26 SV SV2016005264A patent/SV2016005264A/es unknown
- 2016-09-26 ZA ZA2016/06655A patent/ZA201606655B/en unknown
-
2018
- 2018-04-16 US US15/954,021 patent/US10584318B2/en active Active
-
2019
- 2019-08-20 AU AU2019219743A patent/AU2019219743B2/en active Active
- 2019-09-11 CY CY20191100949T patent/CY1122644T1/el unknown
- 2019-09-25 ZA ZA2019/06304A patent/ZA201906304B/en unknown
- 2019-12-05 JP JP2019220178A patent/JP6896050B2/ja active Active
-
2020
- 2020-03-06 US US16/811,484 patent/US10907138B2/en active Active
- 2020-06-17 IL IL275435A patent/IL275435B/en unknown
-
2021
- 2021-08-17 HR HRP20211324TT patent/HRP20211324T1/hr unknown
- 2021-08-19 CY CY20211100743T patent/CY1124727T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210734T1 (hr) | Koštani morfogenetski proteini | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| JP2013172734A5 (enExample) | ||
| MX388977B (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso. | |
| DK3915553T3 (da) | Sammensætninger indeholdende aminosyrer til brug i behandlingen af mitokondrie-dysfunktion-relaterede neurodegenerative sygdomme | |
| EA201990848A1 (ru) | ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B | |
| MX395266B (es) | Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis. | |
| PL3865506T3 (pl) | Białko fuzyjne do zastosowania w leczeniu choroby hvg | |
| EP3354664A4 (en) | PROTEIN CONJUGATE WITH SEVERAL BIOACTIVE POLYPEPTIDES AND IMMUNOGLOBULIN FC REGIONS | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| EP3278810A4 (en) | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
| MX384236B (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| EP3643723C0 (en) | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES COMPRISING SAID NOVEL PEPTIDE AS ACTIVE INGREDIENT | |
| MX2024012898A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| IL269187B1 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal | |
| BR112019020386A2 (pt) | vacinas de peptídeos de pd-1 humana e usos das mesmas | |
| WO2019195714A8 (en) | Methods and compositions for treating skin disease with recombinant microorganisms | |
| EP3530278A4 (en) | COMPOSITION WITH PROTEIN-PHOSPHATASE-1-INHIBITING PEPTIDE FOR THE TREATMENT OF VASCULAR DISEASES | |
| WO2016011201A3 (en) | Epha4 cyclic peptide antagonists for neuroprotection and neural repair |